News

GSK said 90% of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals and the remaining 10% from Allergon in a move to further expand

Safety, tolerability and pharmacokinetics of rVWF combined with rFVIII at a fixed ratio were investigated in the Phase 1 multicenter, international clinical study in 32 patients with type

TLC claims that ProFlow is an improved Prostaglandin E1 emulsion with extended shelf stability of more than two years, developed by TLC with its proprietary formulation, patented worldwide.

Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The product works by interfering with membranes of cancer cells thereby

According to Parexel, the new depot in Singapore and ancillary warehouse in Russia will support its clients in more effectively managing their global clinical trial supply requirements. The

According to Novartis, 82% of the patients achieved disease control and 74% of them achieved tumour reduction at a median follow-up of 9.6 months. The primary endpoint, which

As president of the company, Lau will oversee strategic planning and business development, partnership management and organisation development. Prior to joining China Biologic, Lau served from 2002 to

Under the terms of the agreement, Champions will use its Tumorgraft platform to test the effectiveness of Teva‘s compound in various cancer indications to assist in further clinical

Bristol-Myers Squibb and Otsuka Pharma said that the study results were consistent with 12-month data in which Sprycel demonstrated higher and faster rates of complete cytogenetic response (CCyR)and